Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$2.99
-4.2%		$2.96
$2.32
▼
$5.46
$108.46M0.47237,681 shs128,339 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$2.35
+1.3%		$3.44
$1.96
▼
$8.80
$105.52M-0.1141,352 shs230,594 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
0.00%+4.35%+5.76%-8.50%-24.46%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%+0.87%-29.27%-41.56%-44.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$2.99
-4.2%		$2.96
$2.32
▼
$5.46
$108.46M0.47237,681 shs128,339 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$2.35
+1.3%		$3.44
$1.96
▼
$8.80
$105.52M-0.1141,352 shs230,594 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
0.00%+4.35%+5.76%-8.50%-24.46%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%+0.87%-29.27%-41.56%-44.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
2.40
Hold$8.00167.56% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$10.33339.72% Upside

Current Analyst Ratings Breakdown

Latest ANIX and NERV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Hold
10/6/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/22/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$7.00 ➝ $6.00
9/21/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/17/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
9/3/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/19/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/19/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
8/14/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Mixed$7.50 ➝ $10.00
8/12/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
(Data available from 11/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/AN/AN/AN/A$0.42 per shareN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/A($3.25) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$10.93M-$0.32N/AN/AN/AN/A-76.59%-67.80%1/11/2027 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$293.42M-$28.87N/AN/AN/AN/AN/A-31.72%11/4/2026 (Estimated)

Latest ANIX and NERV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.14N/AN/AN/AN/AN/A
9/9/2026Q3 2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$0.0818-$0.08+$0.0018-$0.08N/AN/A
8/7/2026Q2 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.1933-$0.14+$0.0533-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/A
8.55
8.54
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
20.15
20.14

Institutional Ownership

CompanyInstitutional Ownership
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
29.13%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%

Insider Ownership

CompanyInsider Ownership
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
26.40%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
434.76 million25.59 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
747.75 million46.94 millionOptionable

Recent News About These Companies

Minerva Neurosciences, Inc (NERV) - What Are Investment Firms Thinking About This Stock?
November 2 at 4:32 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173788
Minerva Neurosciences (NASDAQ:NERV) Rating Lowered to Sell at Wall Street Zen
October 31 at 2:08 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31169123
Minerva Neurosciences (NASDAQ:NERV) Cut to "Sell" at Wall Street Zen
October 31 at 1:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-minerva-neurosciences-nasdaq-nerv-cut-to-sell-at-wall-street-zen-2026-10-31/
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
October 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391093/32445/en/minerva-neurosciences-to-participate-in-2026-jefferies-global-healthcare-conference-in-london.html
Minerva Neurosciences (NERV) Set to Announce Quarterly Earnings on Wednesday
October 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-minerva-neurosciences-nerv-set-to-announce-quarterly-earnings-on-wednesday-2026-10-28/
Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
October 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/28/3390025/32445/en/minerva-neurosciences-to-host-in-person-kol-event-to-discuss-roluperidone-for-negative-symptoms-of-schizophrenia.html
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Down 10.02%
October 13, 2026  |  aaii.comA
Minerva Neurosciences, Inc (NASDAQ:NERV) Receives Consensus Recommendation of "Reduce" from Analysts
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-minerva-neurosciences-inc-nasdaq-nerv-receives-consensus-recommendation-of-reduce-from-analysts-2026-10-03/
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
August 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352656/32445/en/minerva-neurosciences-to-participate-in-two-upcoming-investor-conferences.html
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
August 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/07/3341026/32445/en/minerva-neurosciences-provides-second-quarter-2026-financial-results-and-business-updates.html
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304700/32445/en/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs.html
Minerva Neurosciences Launches ATM Offering to Fund Trial
May 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/minerva-neurosciences-launches-atm-offering-to-fund-trial?utm_source=marketbeat.com&utm_medium=referral
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
May 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2924280/all-you-need-to-know-about-minerva-neurosciences-nerv-rating-upgrade-to-buy?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2924280
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
May 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2923961/minerva-neurosciences-nerv-loses-37-5-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=cs-stocknewsapi-ft-tale_of_the_tape|rsi-2923961
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3297009/32445/en/minerva-neurosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference.html
Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
May 5, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68397606-minerva-neurosciences-inc-minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates-399.htm
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287601/32445/en/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates.html
Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/minerva-neurosciences-nerv-price-target-increased-by-31-03-to-9-69/ar-AA21TjoN
Citizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform Recommendation
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/citizens-initiates-coverage-of-minerva-neurosciences-nerv-with-market-outperform-recommendation/ar-AA210hf9
Minerva launched with New Outperform at Citizens on schizophrenia candidate
April 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4575323-minerva-stock-wins-new-outperform-citizens
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline
April 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/minerva-neurosciences-sets-2026-annual-shareholder-meeting-timeline?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anixa Biosciences stock logo

Anixa Biosciences NASDAQ:ANIX

$2.99 -0.13 (-4.17%)
As of 04:00 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$2.35 +0.03 (+1.29%)
Closing price 04:00 PM Eastern
Extended Trading
$2.35 0.00 (-0.21%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas